- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Nicolas Ferreyros: COA's 2023 Community Oncology Conference Celebrating 2 Decades of Achievements
This year's Community Oncology Conference will celebrate 2 decades of achievements in community oncology and begin to chart a path forward for the future, said Nicolas Ferreyros, managing director of policy, advocacy, and communications at Community Oncology Alliance (COA).
This year's Community Oncology Conference will celebrate 2 decades of achievements in community oncology and begin to chart a path forward for the future, said Nicolas Ferreyros, managing director of policy, advocacy, and communications at the Community Oncology Alliance (COA).
Here's what to look forward to at the COA 2023 Community Oncology Conference, which will be held March 22-24, in Kissimee, Florida.
Transcript
What are you looking forward to at the the COA 2023 Community Oncology Conference?
This is going to be my eighth COA conference and I'm really excited about it because we're on track to be, if not 50%, higher than we were last year for attendance; that is a huge milestone for COA, not to mention the fact that it's our 20th anniversary this year.
In addition to having a bigger and better crowd than ever before, we get to celebrate the achievements of community oncology over the last 2 decades, and then also chart the path forward with new topics, new ideas, a fresh leadership. So, it's going to be a really great conference.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
